Myelodysplastic Syndrome Clinical Trial

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Summary

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:

Refractory cytopenia(s), with 1+ of the following:

Platelets <20,000/uL or transfusion dependent
Absolute neutrophil count <500/uL without hematopoietic growth factor support
Absolute reticulocyte count <60,000/uL AND bone marrow cellularity <50% (with < 30% residual hematopoietic cells)
Early myelodysplastic features (bone marrow (BM) blasts <5%), without history of MDS/AML pre-treatment.
Idiopathic SAA with post-HCT graft failure (blood/marrow donor chimerism <5%) requiring a 2nd allogeneic HCT

Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:

Refractory cytopenia(s), with 1+ of the following:

Platelets <20,000/uL or transfusion dependent
Absolute neutrophil count <500/uL without hematopoietic growth factor support
Absolute reticulocyte count <60,000/uL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone >/= 10%
Early myelodysplastic features (bone marrow (BM) blasts <5%) without history of MDS/AML pre-treatment.
Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood/marrow donor chimerism <5%) requiring a 2nd allogeneic HCT
Adequate organ function within 30 days of conditioning regimen

Exclusion Criteria:

Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
Uncontrolled infection
Evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
Known allergy to any of the study components
Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)
Advanced myelodysplastic syndrome (MDS; BM blasts >5%) or acute myeloid leukemia
Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT06412497

Recruitment Status:

Recruiting

Sponsor:

Masonic Cancer Center, University of Minnesota

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Minnesota Masonic Cancer Center
Minneapolis Minnesota, 55455, United States More Info
Christen Ebens
Contact

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT06412497

Recruitment Status:

Recruiting

Sponsor:


Masonic Cancer Center, University of Minnesota

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.